The Network for Public Health Law and the Drug Policy Alliance's fact sheet for harm reduction organizations and individuals outlines the legal rights that apply relative to drug paraphernalia and drug possession laws, rights under the 4th and 5th Amendments, and a list of additional resources.
U.S. overdose deaths dropped ~27% in 2024 compared to the previous year. Learn about the factors behind this decrease, including health-based approaches that are currently at risk.
The Trump Administration is “looking at” changing marijuana’s classification on the Controlled Substances Act (CSA) to Schedule III. Read our factsheet advocating for the removal of marijuana from the CSA entirely.
This report examines how New York's opioid settlement funds have been managed and distributed during their first three years, and makes recommendations for how to ensure future spending reaches communities where the overdose crisis is most severe.
A coalition of courageous parents—who have either lost children to overdose or are fighting to keep theirs alive—marched into the halls of Congress with a clear message: invest in health, treatment and overdose prevention now.
Methadone and buprenorphine, the most effective medications for opioid use disorder (MOUD), promote recovery and save lives by reducing opioid cravings and withdrawal symptoms, while cutting overdose risk in half.
As the overdose crisis continues to take lives in the U.S., the Trump administration is continuing massive budget cuts that will make it harder for people to get the help they need. This funding cuts tracker works to keep up-to-date information on the complicated federal cuts affecting addiction and overdose support.
The MORE Act is a comprehensive criminal justice reform bill that would federally decriminalize marijuana by removing (“descheduling”) it from the Controlled Substances Act (“CSA”). Read our fact sheet to learn more.
Marijuana reform has produced many positive outcomes, new challenges and unintended consequences. Drug Policy Alliance organized a series of focus groups to gather more insights from a wide range of experts.
A toolkit, to support researchers, that highlights stories of the lifesaving studies of drug researchers whose funding has been cut and offers guidance on how to fight back against funding cuts.
